Vera Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 30.53 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.20B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Details
| Name | Vera Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 361 |
| Founded | 2016 |
| Ipo Date | 2021-05-14 |
| Ceo | Marshall Fordyce |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 11.00 |
| Isin | US92337R1014 |
| Cusip | 92337R101 |
| Cik | 1831828 |
| Sic | 2834 |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
Key executives
| Name | Title |
|---|---|
| Dr. Marshall W. Fordyce M.D. | Founder, President, Chief Executive Officer and Director |
| Sean P. Grant M.B.A. | Chief Financial Officer |
| David L. Johnson M.B.A. | Chief Opearating Officer |
| Dr. Robert M. Brenner M.D. | Chief Medical Officer |
| Joseph R. Young M.B.A. | Senior Vice President of Finance and Chief Accounting Officer |
| S. Sandra Park J.D. | Senior Vice President of Legal, Healthcare,Commercial Law, Compliance and Operations |
| Dr. Jane Wright-Mitchell J.D., Pharm.D. | Chief Legal Officer and Secretary |
| Debra Charlesworth | Vice President of Corporate Communications |
| Emma Haywood | Vice President of Marketing |
| Tom Doan | Executive Vice President of Development Operations |
Contact
| Address | 2000 Sierra Point Parkway, Suite 1200, Brisbane, California 94005, United States |
| Phone | 650 770 0077 |
| Website | https://veratx.com |